Education
About Us
Working with TipRanks
Follow Us
Nuvalent (NUVL)
NASDAQ:NUVL
NUVL Stock Chart & Stats
$95.87
-$0.36(-0.45%)
At close: 4:00 PM EST
$95.87
-$0.36(-0.45%)
Day’s Range― - ―
52-Week Range$55.54 - $104.90
Previous CloseN/A
Volume65.93K
Average Volume (3M)535.18K
Market Cap
$6.70B
Enterprise Value$5.30B
Total Cash (Recent Filing)$943.10M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.08
Next Earnings
Mar 04, 2026EPS Estimate
-1.48Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.70
Shares Outstanding67,271,460
10 Day Avg. Volume684,329
30 Day Avg. Volume535,180
Financial Highlights & Ratios
PEG Ratio-0.25
Price to Book (P/B)4.86
Price to Sales (P/S)0.00
P/FCF Ratio-28.09
Enterprise Value/Market Cap0.79
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-13.29
Forecast
1Y Price Target
$123.55Price Target Upside28.87% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering13
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Financial PositionThe company maintained its strong balance sheet position, ending the quarter with $943.1M in cash, cash equivalents, and marketable securities.
Market OpportunityThere is a substantial near-term opportunity associated with 2L+ approval, estimated to be a $1B+ opportunity if Phase II reproduces Phase I results.
Regulatory ProgressThe rolling NDA submission for zidesamtinib in 2L+ ROS1+ NSCLC was completed and is anticipated to receive priority review, which could lead to FDA approval.
Bears Say
Development RisksDownside risks include timeline setbacks for upcoming read-outs and underwhelming clinical data.
Market SentimentShort interest in Nuvalent is relatively high at 13.3% of the float, indicating some market skepticism or potential for stock volatility.
Nuvalent News
NUVL FAQ
What was Nuvalent’s price range in the past 12 months?
Nuvalent lowest stock price was $55.53 and its highest was $104.90 in the past 12 months.
What is Nuvalent’s market cap?
Nuvalent’s market cap is $6.70B.
When is Nuvalent’s upcoming earnings report date?
Nuvalent’s upcoming earnings report date is Mar 04, 2026 which is in 116 days.
How were Nuvalent’s earnings last quarter?
Nuvalent released its earnings results on Oct 30, 2025. The company reported -$1.7 earnings per share for the quarter, missing the consensus estimate of -$1.557 by -$0.143.
Is Nuvalent overvalued?
According to Wall Street analysts Nuvalent’s price is currently Undervalued.
Does Nuvalent pay dividends?
Nuvalent does not currently pay dividends.
What is Nuvalent’s EPS estimate?
Nuvalent’s EPS estimate is -1.48.
How many shares outstanding does Nuvalent have?
Nuvalent has 67,271,460 shares outstanding.
What happened to Nuvalent’s price movement after its last earnings report?
Nuvalent reported an EPS of -$1.7 in its last earnings report, missing expectations of -$1.557. Following the earnings report the stock price went down -4.662%.
Which hedge fund is a major shareholder of Nuvalent?
Currently, no hedge funds are holding shares in NUVL
Nuvalent Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$123.55 (28.87% Upside)
$123.55 (28.87% Upside)
Blogger Sentiment
Bullish
NUVL Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 737.6K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.2%
Last 30 Days ▲ 4.4%
Last 30 Days ▲ 4.4%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
1.89%
12-Months-Change
Fundamentals
Return on Equity
-38.79%
Trailing 12-Months
Asset Growth
-17.58%
Trailing 12-Months
Company Description
Nuvalent
Nuvalent, Inc., a clinical stage biopharmaceutical company, develops therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant mutations and remain active in the presence of mutations conferring resistance to approved and investigational ROS1 inhibitors, which is under Phase I development; and NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, central nervous system-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under Phase I/II clinical trial. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.
NUVL Stock 12 Month Forecast
Average Price Target
$123.55
▲(28.87% Upside)
Technical Analysis
Ownership Overview
32.64% Insiders
22.93% Mutual Funds
<0.01% Other Institutional Investors
33.07% Public Companies and
Individual Investors